Drug Profile

COR 1167

Alternative Names: COR-1167

Latest Information Update: 14 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Corteria Pharmaceuticals
Class Heart failure therapies; Peptides
Mechanism of Action CRF receptor type 2 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Heart failure

Most Recent Events

14 Feb 2025 Corteria Pharmaceuticals completes a phase-I clinical trials in Heart failure in Netherlands (SC) (Corteria Pharmaceuticals website, February 2025)
11 Feb 2025 Corteria Pharmaceuticals plans the phase IIb CRAFT-WHF trial for Heart failure (Adjunctive treatment) in July 2025 (SC) (NCT06815471)
11 Nov 2024 Pharmacodynamics data from a preclincal trial in Heart failure released by Corteria Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com